Bipolar Disorder Drugs and Treatment Market - By Drug Class (Mood Stabilizer, Anti-Psychotic Drugs), By Route of Administration (Oral, Parenteral), By Mechanism of Action (Selective Serotonin Reuptake Inhibitor) & Forecast, 2023 – 2032

Bipolar Disorder Drugs and Treatment Market Size

Bipolar Disorder Drugs and Treatment Market size was valued at around USD 5.2 billion in 2022 and is expected to register over 3.5% CAGR between 2023 and 2032. Government efforts to raise awareness of bipolar diseases will significantly raise the demand for bipolar disorder drugs and treatment, and this trend is anticipated to continue over the projection period.
 

Over the past few years, there has been an increase in focus on mental health, largely due to rising levels of stress among the global population. This could potentially increase the product demand. Other variables that will affect market growth include increasing product approvals, speedy progress in treatment development, and an increase in the number of bipolar disorder cases.
 

Bipolar disorder is a mental health condition that affects an individual’s ability to regulate mood and emotions, which can result in episodes of extreme highs (mania or hypomania) and lows (depression). Bipolar disorder drugs and treatment refer to the medications and therapies used to manage symptoms of bipolar disorder. The primary role of bipolar disorder drugs and treatment is to stabilize mood, reduce the severity and frequency of mood swings, and improve overall quality of life for individuals with the condition.
 

COVID-19 Impact

The COVID-19 pandemic had a slight negative impact on the bipolar disorder drugs and treatment market. Most of the healthcare industry's professionals and resources were directed towards the care of the COVID-19 patients because there were various positive cases of patients who had been exposed to a novel coronavirus. As a result, there was a large decrease in the hospital and healthcare facility's demand for bipolar drugs and treatment. Moreover, to stop the spread of the disease, lockdown restrictions were implemented throughout many nations. This had a significant impact on the global economy, supply chain and had diverse effects on different markets, including those for bipolar disorder drugs and treatments.
 

Bipolar Disorder Drugs and Treatment Market Trends

The increasing prevalence of bipolar disorders is supplementing the demand for bipolar disorder drugs and treatment industry. For instance, according to the Johns Hopkins University report, approximately 9.5% of American adults ages 18 and over suffer from a depressive illness (major depression, bipolar disorder, or dysthymia) each year. Women are nearly twice as likely to suffer from major depression than men. Hence, rising cases of bipolar disorder will foster the market growth.
 

Moreover, several nation’s governments are providing funds for bipolar disorder research and launching awareness programs to remove the stigma attached to the condition and raise treatment & adherence rates among the public. Medical institutions and scientific organizations are also actively participating by conducting research investigations and creating cutting-edge drugs and therapies for bipolar disorder. Such factors will drive the market growth in the forthcoming year.
 

Bipolar Disorder Drugs and Treatment Market Analysis

Numerous medications used to treat bipolar disorder have adverse effects that can include drug addiction, blood sugar and cholesterol problems, thyroid, liver damage, and blurred vision, among others. Studies have revealed that the medication cause few of the serious adverse effects such as teratogenic effects and kidney failure on the developing foetus when used by pregnant women. Additionally, the market dynamics may be significantly impacted by the patent expiry of popular pharmaceuticals in this sector. For instance, patent expiry for Invega, Seroquel, Risperdal, and Zyprexa could slow market growth due to availability of generic drug substitutes in the market.
 

Based on drug class, the bipolar disorder drugs and treatment market is segmented as mood stabilizer, anticonvulsants, anti-psychotic drugs, anti-depressant drugs, and anti-anxiety drugs. The anti-psychotic drugs segment held a majority market value of USD 2.1 billion in 2022. Antipsychotic drugs are used as short-term treatment to control psychotic symptoms such as delusions, hallucinations, and mania in bipolar disorder. These symptoms can occur in acute mania or severe depression. Acute manic psychosis is increasingly treated with antipsychotics such as Cariprazine, Aripiprazole, Olanzapine, and Lurasidone. Thus, increasing cases of psychotic symptoms will supplement the segmental growth. Furthermore, increasing focus on combination therapy to treat bipolar disorder will boost the market growth. Antipsychotic drugs are often used in combination with mood stabilizers and other medications which is likely to contribute to growth in the market.
 

Based on route of administration, the market is segmented as oral, parenteral, and other route of administrations. The oral segment held a dominant market share of 59.2% in 2022 and is expected to grow at a significant pace during the analysis period. Oral medications are easy to take and do not require any special equipment or training. Thus, the oral route of administration is one of the most common and preferred method for delivering bipolar disorder medications. Furthermore, the availability of broad range of oral medications for the bipolar treatment is likely to contribute to the growth of the bipolar disorder drugs and treatment market. Moreover, flexibility in dosing and cost effectiveness of oral bipolar disorder drugs are expected to drive the market growth in the forthcoming year.
 

Based on mechanism of action, the market is segmented as selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, tricyclic antidepressant drug, beta blockers, and other mechanism of actions. The selective serotonin reuptake inhibitor segment held a dominant market share in 2022 and is expected to grow at a considerable pace of 3.4% between 2023 to 2032. Advancements in drug development is contributing to bipolar disorder drugs and treatment market expansion. The development of new medications and therapy with fewer side effects is making treatment more tolerable for patients. Additionally new drugs are being developed that target different aspects of bipolar disorder, providing healthcare providers with a wider range of treatment options. This advancement in drug development is expected to continue to drive the market statistics in the coming year.
 

U.S. bipolar disorder drugs and treatment market dominated the North America region with majority business share and a revenue of USD 1.9 billion in 2022. This majority market share is attributable to the increasing prevalence of bipolar disorders. This can be attributed to the insufficient sleep, trend of substance abuse, and high-stress levels amongst the population. Also, government initiatives aimed at raising awareness and support for patients suffering from mental disorder are expected to boost the market growth in the region. For instance, the Department of Health and Human Services (HHS), through the Substance Abuse and Mental Health Services Administration (SAMHSA), and the Office of Minority Health (OMH) funded nearly $35 million to strengthen and expand community behavioral & mental health services including software for America’s children and young adults in 2022. Such initiative is anticipated to accelerate the market growth in the forecast period. Moreover, the presence of advanced healthcare infrastructure coupled with increasing healthcare expenditure will supplement the market growth.
 

Bipolar Disorder Drugs & Treatment Market Share

Some of the major market players operating in the bipolar disorder drugs and treatment market are

• GlaxoSmithKline (GSK)
• Pfizer Inc.
• Eli Lily
• AbbVie Inc.
• Otsuka Holdings Co.Ltd.
• AstraZeneca
• Novartis AG
• Janssen Pharmaceuticals

These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.
 

Bipolar Disorder Drugs and Treatment Industry News:

• In September 2022, Otsuka America Pharmaceutical, Inc., (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the U.S. FDA approved their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults. This approval helped the company to expand their customer base.
   
• In May 2019, Allergan plc and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine). This approval expanded use of VRAYLAR to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults. This strategy helped the company to expand and grow.
   

The bipolar disorder drugs and treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Drug Class

• Mood Stabilizer
• Anticonvulsants
• Anti-Psychotic Drugs
• Anti-Depressant Drugs
• Anti-Anxiety Drugs

By Route of Administration

• Oral
• Parenteral
• Other route of administrations

By Mechanism of Action

• Selective Serotonin Reuptake Inhibitor
• Serotonin Norepinephrine Reuptake Inhibitor,
• Tricyclic Antidepressant Drug
• Beta Blockers
• Other mechanism of actions

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Switzerland
  • Netherlands
  • Rest of Europe 
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Indonesia
  • Vietnam
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
  • Peru
  • Rest of Latin America 
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Rest of MEA